Search results
Added:
10 months ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design…
View more
Added:
1 year ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had…
View more
Added:
1 year ago
AF Symposium 24 — Dr Yury Malyshev (Mount Sinai Hospital, US) joins us to discuss the findings from three studies focusing on the long-term effects of pulsed-field ablation (PFA) on coronary arteries.QuestionsWhat is known currently about the effect of PFA in Coronary Arteries? What is the importance of this topic?What was the study design and cohort?What are the key findings?Who are the take…
View more
Added:
1 month ago
ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip.Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of…
View more
Added:
2 months ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,…
View more
Added:
2 weeks ago
New York Valves 25 - A substudy of TRISCEND II investigating the effect of transcatheter tricuspid valve replacement (TTVR) on preference-weighted health status showed significant benefits in patients who received TTVR.We are joined by Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, US) to discuss the findings from a substudy of the TRISCEND II trial, which aimed to create an…
View more
Added:
1 month ago
ESC HF 25 - Secondary analysis of the FINEARTS-HF study shows finerenone treatment favourably influenced the risk of early heart failure readmission.Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, San Francisco, US) discusses findings from the prespecified secondary analysis of the FINEARTS-HF trial (NCT04435626; Bayer). The placebo-controlled primary analysis investigated the…
View more
Added:
11 months ago
Added:
11 months ago
Added:
8 months ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an…
View more